Prophylaxis of HIV Infection following Occupational Exposure

Abstract

Spanish

French

OBJECTIVE:

To review the risk of HIV infection following occupational exposure, the theoretical basis for chemoprophylaxis, investigative experience with chemoprophylaxis in animals and humans, and the economic aspects of postexposure chemoprophylaxis.

DATA SOURCES:

English-language articles and conference proceedings pertaining to the risk of occupational HIV infection and to postexposure chemoprophylaxis.

STUDY SELECTION:

Studies evaluating chemoprophylaxis of HIV infection following occupational exposure were selected for review. Abstracts reporting ongoing clinical trials were also included.

DATA EXTRACTION:

In vitro studies are discussed to provide the immunologic rationale for chemoprophylaxis. Animal studies examining the efficacy of chemoprophylaxis in preventing non-HIV retroviral infection are reviewed, and their applicability to human HIV infection is critically evaluated. Human studies and case reports describing attempts at chemoprophylaxis of HIV infection following occupational exposure are discussed.

DATA SYNTHESIS:

Chemoprophylaxis of HIV infection following occupational exposure has focused on the use of zidovudine (ZDV) because it was previously the only antiretroviral agent approved for treating HIV infection. Animal models of retroviral infection provide conflicting data regarding the efficacy of ZDV chemoprophylaxis, and there are important questions about the applicability of animal data to human HIV infection because of differences in natural histories of non-HIV retroviral infections, inoculum size, dosing of ZDV, and routes of infection. Human surveillance studies are thus far inadequate to determine the efficacy of ZDV prophylaxis because of the very low HIV seroconversion rates following occupational exposure. ZDV is well tolerated during short-term administration in people without HIV infection, but long-term safety is unknown. In addition, the true cost-benefit ratio of ZDV chemoprophylaxis is uncertain.

CONCLUSIONS:

Current data from in vitro, animal, and human studies are inadequate to define the appropriate role of ZDV in preventing HIV infection following occupational exposure. Limited toxicity data and the high cost of treatment must be weighed against the theoretical benefits of ZDV use in this setting. The decision to employ ZDV for postexposure prophylaxis must ultimately be based on existing institutional policies, the attitude of the responsible physician regarding such practice, and/or the desires of the exposed healthcare worker after being properly informed of potential risks and benefits.

Get full access to this article

View all access options for this article.

References

Needlestick transmission of HTLV-III from a patient infected in Africa (letter). Lancet 1984; 2: 1376–7.

Centers for Disease Control. Public Health Service statement on management of occupational exposure to human immunodeficiency virus (HIV), including considerations regarding zidovudine post-exposure use. MMWR 1990; 39 (RR-1):1–14.

Henry

Campbell

. Needlestick/sharps injuries and HIV exposure during 1990: National estimates based on a survey of U.S. hospitals (abstract). Int Conf AIDS 1992; 8: C269.

McCray

, Co-operative Needlestick Surveillance Group. Occupational risk of the acquired immune deficiency syndrome among health care workers. N Engl J Med 1986; 314: 1127–32.

Battan

Raviglione

Cortes

Sugar

Garner

Raviglione

. Risk of exposure to HIV-infected body fluids among medical housestaff (MHS) (abstract 957). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 245.

Gerberding

Littell

Brown

Raniro

. Cumulative risk of HIV and hepatitis B (HBV) among health care workers (HCW): longterm serologic followup and gene amplification for latent HIV infection (abstract 959). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.

Fahey

Beekmann

Schmitt

Fedio

Henderson

. Assessment of risk for occupational HIV-l infection in health care workers (HCW) and safety of zidovudine (AZT) administered as postexposure chemoprophylaxis for occupational exposures (abstract 960). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.

Marcus

Tokars

Culver

McKibben

Bell

. Zidovudine use after occupational exposure to HIV-infected blood (abstract 979). Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 262.

McEvoy

Ported

Mortimer

Simmons

Shanson

. Prospective study of clinical, laboratory, and ancillary staff with accidental exposures to blood or body fluids from patients infected with HIV. Br Med J 1987; 294: 1595–7.

10.

Puro

Ippolito

, Italian Study Group on Occupational Risk of HIV Infection. Zidovudine in post-exposure prophylaxis of healthcare workers (letter). Lancet 1990; 335: 1166–7.

11.

Jagger

Hunt

Brand-Elnaggar

Pearson

. Rates of needlestick injury caused by various devices in a university hospital. N Engl J Med 1988; 319: 284–8.

12.

Centers for Disease Control. Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other blood-borne pathogens in health-care settings. MMWR 1988; 37: 377–88.

13.

Centers for Disease Control. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR 1989; 38 (suppl 6):S1–S37.

14.

Hayward

Shapiro

. A national study of AIDS and residency training: Experiences, concerns and consequences. Ann Intern Med 1991; 114: 23–32.

15.

Kneer

Sinnott

Shaw

. Percutaneous and mucocutaneous exposure of third year medical students to blood and blood-tinged body fluids (abstract 972). Program and abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 261.

16.

Tokars

Marcus

Culver

Bell

. Blood contacts during surgical procedures (SPs) (abstract 958). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.

17.

Gerberding

Wugofsky

Berkvan

Mangione

Rinaldi

Guokas

. Facilitated surveillance and post-exposure AZT prophylaxis for health care workers (HCW): the San Francisco General Hospital model (abstract 961). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.

18.

St. Louis

Rauch

Petersen

Anderson

Schable

Dondero

. Seroprevalence rates of human immunodeficiency virus infection at sentinel hospitals in the United States. N Engl J Med 1990; 323: 213–8.

19.

Kelen

Fritz

Qaquish

Brookmeyer

Baker

Kline

. Unrecognized human immunodeficiency virus infection in emergency department patients. N Engl J Med 1988; 318: 1645–50.

20.

Kelen

Fritz

Qaquish

Floccare

DiGiovanna

Baker

. Substantial increase in human immunodeficiency virus (HIV-l) infection in critically ill emergency patients: 1986 and 1987 compared. Ann Emerg Med 1989; 18: 378–82.

21.

Rhee

Albertson

Kizer

Hughes

Ascher

. The HIV-l seroprevalence rate of injured patients admitted through California emergency departments. Ann Emerg Med 1991; 20: 969–72.

22.

Henderson

Fahey

Willy

Schmitt

Carey

Koziol

. Risk for occupational transmission of human immunodeficiency virus type l (HIV-l) associated with clinical exposures: A prospective evaluation. Ann Intern Med 1990; 113: 740–6.

23.

Ramsey

Smith

Reinarz

. Prospective evaluation of 44 health care workers exposed to human immunodeficiency virus-l, with one seroconversion (abstract). Clin Res 1988; 36: 22A.

24.

Gerberding

Bryant-LeBlanc

Nelson

Moss

Osmond

Chambers

. Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. J Infect Dis 1987; 156: 1–8.

25.

Kuhls

Viker

Parris

Garakian

Sullivan-Bolyai

Cherry

. Occupational risk of HIV, HBV, and HSV-2 infections in health care personnel caring for AIDS patients. Am J Public Health 1987; 77: 1306–9.

26.

Wormser

Joline

Sivak

Arlin

. Human immunodeficiency virus infections: Considerations for health care workers. Bull N Y Acad Med 1988; 64: 203–15.

27.

Henderson

. HIV-l in the health-care setting. In: Mandell

Douglas

Jr Bennett

, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 2221–36.

28.

Centers for Disease Control. Update: Acquired immunodeficiency syndrome and human immunodeficiency virus infection among health care workers. MMWR 1988; 37: 229–39.

29.

Stricof

Morse

. HTLV-III/LAV seroconversion following a deep intramuscular needlestick injury (letter). N Engl J Med 1986; 314: 1115.

30.

Neisson-Vernant

Arfi

Mathez

Leibowitch

Monplaisir

. Needlestick HIV seroconversion in a nurse (letter). Lancet 1986; 2: 814.

31.

Oksenhendler

Harzie

Le Roux

. HIV infection with seroconversion after a superficial needlestick injury to the finger (letter). N Engl J Med 1986; 315: 582.

32.

Centers for Disease Control. Recommendations for prevention of HIV transmission in health-care settings. MMWR 1987; 36 (suppl 2S):1–19S.

33.

Gerberding

Henderson

. Design of rational infection control policies for human immunodeficiency virus infection. J Infect Dis 1987; 156: 861–4.

34.

Weiss

Goedert

Gartner

Popovic

Waters

Markham

. Risk of human immunodeficiency virus (HIV-l) infection among laboratory workers. Science 1988; 239: 68–71.

35.

Wallace

Harrison

. HIV seroconversion with progressive disease in a health care worker after needlestick injury. Lancet 1988; 1: 1454.

36.

Looke

DFM

Grove

. Failed prophylactic zidovudine after needlestick injury (letter). Lancet 1990; 335: 1280.

37.

Centers for Disease Control. Update: Human immunodeficiency virus infections in health-care workers exposed to blood of infected patients. MMWR 1987; 36: 285–9.

38.

Gioannini

Sinicco

Cariti

Lucchini

Paggi

Giachino

. HIV infection acquired by a nurse. Eur J Epidemiol 1988; 4: 119–20.

39.

Tokars

Marcus

Culver

McKibben

Bell

. Zidovudine (AZT) use after occupational exposure to HIV-infected blood (abstract 490). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 168.

40.

Gerberding

Hopewell

Kanninsky

Sande

. Transmission of hepatitis B without transmission of AIDS by accidental needlestick. N Engl J Med 1985; 312: 56–7.

41.

Horsburgh

Jr Ou

Jason

Holmberg

Longini

Jr Schable

. Duration of human immunodeficiency virus infection before detection of antibody. Lancet 1989; 2: 637–40.

42.

Hessol

Byers

Lifson

O'Malley

Cannon

Barnhart

. Relationship between AIDS latency period and AIDS survival time in homosexual and bisexual men. J Acquir Immune Defic Syndr 1990; 3: 1078–85.

43.

Durand

Le Jeunne

Hugues

F-C

. Failure of prophylactic zidovudine after suicidal self-inoculation of HIV-infected blood (letter). N Engl J Med 1991; 324: 1062.

44.

Jones

. HIV transmission by stabbing despite zidovudine prophylaxis (letter). Lancet 1991; 338: 884.

45.

Lange

JMA

Boucher

CAB

Hollak

CEM

Wiltink

EHH

Reiss

van Royen

. Failure of zidovudine prophylaxis after accidental exposure to HIV-l. N Engl J Med 1990; 322: 1375–7.

46.

Gollins

Porterfield

. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 1986; 321: 244–6.

47.

Robert-Guroff

Brown

Gallo

. HTLV-III neutralizing antibodies in patients with AIDS and AIDS related complex. Nature 1985; 316: 72–4.

48.

Matthews

Langlois

Robey

Chang

Gallo

Fischinger

. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A 1986; 83: 9709–13.

49.

Weiss

Clapham

Cheingsong-Popov

Dalgleish

Carne

Weller

IVD

. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985; 316: 69–72.

50.

Weiss

Clapham

Weber

Dalgleish

Lasky

Berman

. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 1986; 324: 572.

51.

Salk

. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987; 327: 473–6.

52.

Nara

Robey

Gonda

Cater

Fischinger

. Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp 120. Proc Natl Acad Sci U S A 1987; 84: 3797–801.

53.

Lyerly

Matthews

Langlois

Bolognesi

Weinhold

. Human T-cell lymphotropic virus III_B glycoprotein (gp l20) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A 1987; 84: 4601–5.

54.

Lyerly

Reed

Matthews

Langlois

Ahearne

Petteway

Jr . Anti-GP120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 1987; 3: 409–22.

55.

Weinhold

Lyerly

Matthews

Tyler

Ahearne

Stine

. Cellular anti-GP120 cytolytic reactivities in HIV-l seropositive individuals. Lancet 1988; 1: 902–5.

56.

Walker

Chakrabarti

Moss

Paradis

Flynn

Durno

. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987; 328: 345–8.

57.

Plata

Autran

Matrins

Pedroza L

Wain-Hobson

Raphaël

Mayaud

. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature 1987; 328: 348–51.

58.

Ranki

Valle

S-L

Krohn

Antonen

Allain

J-P

Leuther

. Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection. Lancet 1987; 1: 589–93.

59.

Henderson

Gerberding

. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: An interim analysis. J Infect Dis 1989; 160: 321–7.

60.

Henderson

. Postexposure chemoprophylaxis for occupational exposure to human immunodeficiency virus type l: Current status and prospects for the future. Am J Med 1991; 91 (suppl 3B):312–9S.

61.

Fisher

Bertonis

Meier

Johnson

Costopoulos

Liu

. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988; 331: 76–8.

62.

Hussey

Richardson

Kowalski

Brown

Chang

H-C

Siliciano

. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988; 331: 78–81.

63.

Deen

McDougal

Inacker

Folena-Wasserman

Arthos

Rosenberg

. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988; 331: 82–4.

64.

Traunecker

Lüke

Karjalainen

. Soluble CD4 molecules neutralize human immunodeficiency virus type l. Nature 1988; 331: 84–6.

65.

Kahn

Allan

Hodges

Kaplan

Arri

Fitch

. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1990; 112: 254–61.

66.

Schooley

Merigan

Gaut

Hirsch

Holodniy

Flynn

. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med 1990; 112: 247–53.

67.

Bolognesi

. Prospects for prevention of and early intervention against HIV. JAMA 1989; 261: 3007–13.

68.

Fletcher

Rhame

Cummins

Balfour

Jr Allain

J-P

. HIV immune globulin (HIVIG) pharmacokinetics in persons with AIDS (abstract). Clin Pharmacol Ther 1991; 49: 198.

69.

Sheridan

Aurelian

Donnenberg

Quinn

. Cell-mediated immunity of cytomegalovirus (CMV) and herpes simplex virus (HSV) antigens in the acquired immunodeficiency syndrome: Interleukin-1 and interleukin-2 modify in vitro responses. J Clin Immunol 1984; 4: 304–11.

70.

Rook

Masur

Lane

Frederick

Kasahara

MacHer

. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983; 72: 398–403.

71.

Ruscetti

Mikovits

Kalyanaraman

Overton

Stevenson

Stromberg

. Analysis of effector mechanism against HTLV-1 and HTLV-III/LAV against lymphoid cells. J Immunol 1986; 136: 3619–24.

72.

McGrath

Hwang

Caldwell

Gaston

Luk

K-C

. GLQ223: An inhibitor of human immunodeficiency virus replication in acutely and chronically infected cells of lymphocyte and mononuclear phagocyte lineage. Proc Natl Acad Sci U S A 1989; 86: 2844–8.

73.

Ruprecht

O'Brien

Rossoni

Lehrman

. Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature 1986; 323: 467–9.

74.

Tavares

Roneker

Johnston

Lehrman

de Noronha

. 3′-Azido-3′-deoxythymidine in feline leukemia virus-infected cats: A model for therapy and prophylaxis of AIDS. Cancer Res 1987; 47: 3190–4.

75.

Mathes

Polas

Hayes

Swenson

Johnson

Kociba

. Pre- and postexposure chemoprophylaxis: Evidence that 3′-azido-3′-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother 1992; 36: 2715–21.

76.

Schinazi

Anderson

Fultz

McClure

. Prophylaxis with antiretroviral agents in rhesus macaques inoculated with simian immunodeficiency virus (abstract 962). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 246.

77.

Gerberding

Marx

Gould

Joye

Lackner

. Simian model of retrovirus chemoprophylaxis with constant infusion zidovudine ± interferon alpha (abstract 976). Program and abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 261.

78.

McCune

Namikawa

Shih

C-C

Rabin

Kaneshima

. 3′-Azido-3′-deoxythymidine suppresses HIV infection in the SCID-hu mouse. Science 1990; 247: 564–6.

79.

Shih

C-C

Kaneshima

Rabin

Namikawa

Sager

McGowan

. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis 1991; 163: 625–7.

80.

Reitz

Jr Gallo

. Human immunodeficiency virus. In: Mandell

Douglas

Jr Bennett

, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 1344–52.

81.

Rota

Hirsch

. Infection of monocyte/macrophages by human T-lymphotropic virus type III. J Clin Invest 1986; 77: 1712–5.

82.

Gartner

Markovits

Kaplan

Gallo

Popovic

. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986; 233: 215–24.

83.

Folks

Kessler

Orenstein

Justement

Jaffe

Fauci

. Infection and replication of human immunodeficiency virus-l (HIV-l) in purified progenitor cells of normal human bone marrow. Science 1988; 242: 919–22.

84.

Smith

Brian

Pagano

. Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol 1987; 61: 3769–73.

85.

Fischl

Richman

Grieco

Gottlieb

Volberding

Laskin

. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185–91.

86.

Volberding

Lagakos

Koch

Pettinelli

Myers

Booth

. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941–9.

87.

Gerberding

Fahrner

Berkvan

Thibault

. Zidovudine post-exposure chemoprophylaxis for health care workers exposed to HIV at San Francisco General (abstract 977). Program and abstracts of the 31 st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 262.

88.

LaFon

Mooney

McMullen

Pattishall

Smiley

Rogers

. A double-blind, placebo-controlled study of the safety and efficacy of Retrovir (zidovudine, ZDV) as a chemoprophy-lactic agent in health care workers (HCW) exposed to HIV (abstract 489). Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 21–24, 1990. Washington, DC: American Society for Microbiology, 1990: 167.

89.

LaFon

Lehrman

Barry

. Prophylactically administered Retrovir in health care workers potentially exposed to the human immunodeficiency virus. J Infect Dis 1988; 158: 503.

90.

Morgan

. HIV and needlestick injuries (letter). Lancet 1990; 335: 1280.

91.

Fischl

Parker

Pettinelli

Wulfsohn

Hirsch

Collier

. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1009–14.

92.

Moore

Creagh-Kirk

Keruly

Link

Wang

M-C

Richman

. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Arch Intern Med 1991; 151: 981–6.

93.

Bernard

Boulley

A-M

Perol

Rouzioux

Colau

J-C

. Failure of zidovudine prophylaxis after exposure to HIV-l (letter). N Engl J Med 1990; 323: 916.

94.

Sperling

Stratton

O'Sullivan

Boyer

Watts

Lambert

. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. N Engl J Med 1992; 326: 857–61.

95.

Sacks

Rose

. Zidovudine prophylaxis for needlestick exposure to human immunodeficiency virus: A decision analysis. J Gen Intern Med 1990; 5: 132–7.

96.

Bloom

Glied

. The evolution of AIDS economic research. Health Policy 1989; 11: 187–96.

97.

Allen

Read

Gafni

. Zidovudine for chemoprophylaxis after occupational exposure to HIV-infected blood: An economic evaluation. Clin Infect Dis 1992; 14: 822–30.

98.

Lui

K-J

Darrow

Rutherford

. A model-based estimate of the mean incubation period for AIDS in homosexual men. Science 1988; 240: 1333–5.

99.

Rothenberg

Woelfel

Stoneburner

Milberg

Parker

Truman

. Survival with the acquired immunodeficiency syndrome: Experience with 5833 cases in New York City. N Engl J Med 1987; 317: 1297–302.

100.

Payne

Lemp

Rutherford

. Survival following AIDS-related opportunistic infections in San Francisco (abstract 1249). Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 23–26, 1988. Washington, DC: American Society for Microbiology, 1988: 332.

101.

Rhame

Russell

. Zidovudine after occupational exposure to the human immunodeficiency virus (letter). N Engl J Med 1991; 324: 1266–7.

102.

Erice

Strike

Sannerud

Balfour

Jr . Zidovudine (ZDV) susceptibilities of human immunodeficiency virus type l (HIV-l) isolates from patients with acute HIV-l infection treated with ZDV (abstract 569). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 205.

103.

Larder

Darby

Richman

. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731–4.

104.

Erice

Mayers

Sannerud

Fischl

Balfour

Jr . Zidovudine (ZDV) susceptibilities and genotypic characterization of HIV-l isolates from symptomatic patients with 200–800 CD4+ cells/mm³ (abstract 576). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 206.

105.

Principi

Vago

Massironi

Tornaghi

de Pasquale

Marchisio

. HIV-l reverse transcriptase mutations in children treated with zidovudine (abstract 570). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 205.

106.

Fitzgibbon

Farnham

Sperber

Mazar

Dubin

. AZT and ddC resistance mutations in HIV from a patient treated with both agents (abstract 574). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 206.

107.

Husson

Shirasaka

Butler

Pizzo

Mitsuya

. High level resistance to AZT, but not to ddC or ddI in HIV from children receiving long-term antiretroviral therapy (abstract 571). Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct. 11–14, 1992. Washington, DC: American Society for Microbiology, 1992: 206.

108.

Shirasaka

Yarchoan

O'Brien

Husson

Anderson

Kojima

. HIV-1 drug-resistance profile in vivo: A comparison of azidothymidine (AZT), dideoxycytidine (ddC), and dideoxyinosine (ddI) (abstract) Int Conf AIDS 1992; 8: B182.

109.

McLeod

McGrath

Connolly

Allan

Hammer

. Dideoxyinosine (ddI) and zidovudine (AZT) resistance patterns in clinical isolates of HIV-1 (abstract 1355). Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 29-Oct. 2, 1991. Washington, DC: American Society for Microbiology, 1991: 325.